NIH

CLINICAL TRIAL FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

The research study sets out to learn about changes in the genetic makeup of CLL during the early phase of treatment with venetoclax. The initial phase of venetoclax therapy can be medically andlogistically challenging and patients will receive expert medical care at the National Institutes of Health (NIH).

PARTNER IN RESEARCH

The NIH is looking for patients with CLL that has progressed despite treatment or were intolerant to therapy.

TREATMENT AT NIH

Patients are provided the novel agent venetoclax for roughly five weeks. There is no charge for study-related tests, procedures or medications at NIH. Patients have NIH follow-up every six months. Compensation for travel and lodging is provided.

CONTINUE AT LOCAL PROVIDERS

After the initial phase of venetoclax is complete, patients transition to the care of their local hematologist/oncologist to receive venetoclax through their provider.

NIH Clinical Center
Office of Patient Recruitment
1-800-411-1222 (refer to study 19-H-0111)
TTY for the deaf or hard of hearing: 1-866-411-1010
Se habla español
prpl@cc.nih.gov
https://go.usa.gov/xyrqb